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Coagulation occurs not only intravascularly in a milieu containing the complete 
plasma clotting system, but also extravascularly during  hemostasis and  inflam- 
mation  (1-3).  To  more  fully  understand  extravascular  coagulation  reactions, 
especially those occurring in lung disorders characterized by alveolar edema and 
capillary  leak syndromes  (3,  4),  we recently  investigated  alveolar  macrophage 
populations isolated from rabbits. In these studies, the macrophages were found 
to contain tissue factor activity in amounts that increase in vivo and in vitro with 
cell  maturation.  Immunologic  lung  reactions  induced  by  bacillus  Calmette- 
Gu~rin had the effect of stimulating pulmonary accumulation of the cells, mostly 
as mature forms expressing large amounts of tissue factor procoagulant (5). The 
role of tissue factor in coagulation is to initiate the extrinsic clotting pathway by 
complexing with factor VII, and this complex activates factor X to Xa, which in 
turn interacts with factor V. The latter protein is required for rapid proteolytic 
prothrombin  to thrombin  conversion  by factor Xa,  and  is  therefore a  central 
cofactor in the cascade of reactions leading to fibrin formation (6,  7). To date, 
only the hepatocyte is widely accepted as a cellular source of factor V (8, 9). 
In experiments reported here, we investigated production by alveolar macro- 
phages of additional  procoagulants comprising the extrinsic and common final 
clotting pathways. We found that these macrophages generate factor V activity, 
particularly at intermediate stages of cellular maturation.  Factor V procoagulant 
activity derived from this macrophage source may contribute to clotting reactions 
and fibrin deposition in the lung. 
Materials and Methods 
Animals and Cell Procurement.  Alveolar macrophages were isolated from New Zealand 
White female rabbits by bronchoalveolar lavage and separated into subpopulations using 
discontinuous Percoll gradients as previously  described (5). Briefly, animals were killed 
by intravenous injection  of 3 ml of pentobarbitol (1 g/ml).  The lungs were excised and 
lavaged  with  80  ml  of 0.15  M sterile  saline. Cells  in  lavage  fluids  were pelleted  by 
centrifugation,  suspended in  saline,  and  further  purified  by centrifugation  through  a 
discontinuous Percoll gradient of densities  1.055,  1.060,  1.064,  1.068, and  1.070 g/ml. 
Cells  banding  at  density  interfaces  were carefully  collected  using  a  peristaltic  pump, 
washed, and suspended in phosphate-buffered saline at a concentration of 4 x  10~cells/ 
ml.  Maturation  was evaluated  by examining  Wright-stained  smears  of the  individual, 
freshly isolated macrophage subpopulations,  as previously described (5). Briefly, by mor- 
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phologic examination using a light microscope, it was observed that cells of low density 
(more mature) had relatively large cytoplasmic diameters (C),  low ratios of nuclear  to 
cytoplasmic diameters (N/C), and extensive cytoplasmic granulation and vacuolation as 
compared with denser (less mature) cells.  For quantitative morphometric studies, a light- 
pen digitizer system was used to measure diameters of projected cell images, and an on- 
line computer calculated mean values of C and N/C. These morphometric studies showed 
that C increased progressively from a mean of 13 #m in the 1.055 g/ml fraction to 19 #m 
in the  1.070 g/ml fraction.  By contrast,  N/C ratios progressively decreased from 5.6  x 
10 -1 to 6.7 x  10 -1 from the highest- to lowest-density subpopulations. These quantitative 
findings of stepwise increases of C and decreases of N/C, correlating with density changes 
and morphologic appearance, provide evidence that maturity in the macrophage subpop- 
ulations progressively increased from the 1.055-g/ml to the 1.070-g/ml fractions (5). The 
unfractionated  cell  preparations  and  the  five purified  subpopulations  contained  98% 
macrophages as determined by nonspecific esterase and Wright  staining, and the cells 
were 95% viable, as tested by trypan blue dye exclusion. 
Cell Culture.  Unfractionated macrophages and the subpopulations were suspended in 
phosphate-buffered saline and incubated at a concentration of 4 x  106 cells/ml in either 
Labtek flaskettes (Miles  Laboratories,  Inc.,  Naperville,  IL) or in  24-well  Costar plates 
(Costar, Data Packaging, Cambridge, MA) in 1-ml or 0.25-ml cultures, respectively. After 
incubation for 2 h at 37°C in humidified air with 5% CO2, the phosphate-buffered saline 
overlying adherent macrophages was removed and replaced by culture medium consisting 
of minimum essential  medium (Flow  Laboratories,  Inc.,  McLean,  VA).  Added  to the 
minimum essential medium was 100 U/ml penicillin,  100 ~,g/ml streptomycin, and 0.5% 
heated (100 ° C, 30 min) lactoalbumin hydrolysate (Becton, Dickinson & Co., Cockeysville, 
MD).  The serum-free cultures  were continued  for periods ranging from 2  to 48  h  as 
reported in the Results. In some experiments, endotoxin type BII (kindly provided by Dr. 
David Morrison of Emory University, Atlanta, GA) was added to cultured cells at 0.1-10 
#g/ml.  After cell  culture,  supernatants  to be assayed for coagulation  factors were re- 
covered with a pipette and centrifuged to remove any detached cells. The detached cells, 
pelleted by centrifugation of supernatants, were then recovered and added to attached 
cells harvested separately by scraping the flasks or microtiter plate wells  with a rubber 
policeman.  Samples not  assayed immediately were  stored  at  -20°C  in  20%  glycerin. 
Under these conditions, factor V activity was stable during storage, but in the absence of 
glycerin, factor V was labile. 
Coagulation Assays.  Factor  V  activity was measured in  culture supernatants  using a 
two-stage coagulation test with purified coagulation factors (6). Preliminary studies showed 
that similar results were obtained if assays were performed using cultured cells suspended 
in the supernatants rather than supernatants alone. In the first stage of the assay, thrombin 
was generated from prothrombin by factor Xa during a 5-min incubation at 37 °C in the 
presence of lipid vesicles, factor V in the sample, and calcium chloride. This reaction was 
stopped by diluting  the  reaction  mixture  10-fold with  chilled  saline.  The amounts of 
thrombin produced were measured in the second stage of assay as clotting times (seconds) 
obtained after adding the diluted  first-stage mixture to fibrinogen, using a  Fibrometer 
(Becton, Dickinson & Co.). These clotting times were converted to thrombin equivalents 
(National Institutes of Health thrombin units per milliliter of supernatant) by referral to 
calibration curves made daily. The curves showed log-log plots of clotting times measured 
after adding known amounts of serially diluted thrombin standard to fibrinogen (6). The 
standard curves were linear from 5 to 19 thrombin units/ml at lower limits to 395 units/ 
ml at upper limits. Duplicate measurements varied by <10%. Incubation mixtures for the 
first stage contained 30 ul of test material (e.g., supernatants) plus 30 #1 of components at 
the following concentrations: purified bovine Xa at 0.04 unit/ml, purified human pro- 
thrombin  at  0.2  unit/ml,  rabbit  brain  cephalin  at 6.6  nmol  lipid phosphorus/ml,  and 
0.025  M CaClu.  For the second stage of assay, 90 ~1 of purified bovine fibrinogen at 5 
mg/ml was added along with 90 ~1 of the incubated first-stage mixture diluted  10-fold. 
Controls showed that reaction mixture components used for assaying cultured cells and 
supernatants  were  present  in  excess  in  the  two-stage  test,  and  using  10-fold-higher 1882  ALVEOLAR  MACROPHAGE  FACTOR  V  ACTIVITY 
concentrations of CaCI2, lipid, factor Xa, prothrombin, and fibrinogen had no effect on 
the specificity of the assay. A  linear relationship between the logarithms of the (initial) 
rates of thrombin generation and the concentrations of factor V from macrophage cultures 
was found. Brain thromboplastin standards were without effect on clotting times obtained 
in the two-stage assay for factor V. In selected experiments, test samples were preincubated 
with catalytic amounts of thrombin (0.5-2 units/ml) to determine if the factor V activity 
in the samples was present as V or Va (10).  The thrombin-activated samples were diluted 
two- to five-fold before testing for factor V to avoid interference in the assay by the added 
thrombin. Purified reagents for the two-stage assay of factor V activity were from Sigma 
Chemical Co., St.  Louis, MO.  Some experiments used lysates, which were prepared by 
freezing  and  thawing  cells  in  medium  with  and  without  added  glycerin  at  20%  for 
stabilization of factor V. 
Tissue factor activity was quantitated  using a  one-stage clotting test.  Culture  super- 
natants or cell lysates that were suspended in fresh medium or supernatant at 4  ×  106 
cells/ml (60 #1) were added to 60 #1 of 0.025 M CaCI2 and platelet-poor rabbit plasma (60 
~1). Clot formation time was measured using a Fibrometer, and times were converted into 
tissue factor units using log-log plots of the clotting times obtained with serial dilutions of 
a thromboplastin standard (5). By definition,  1,000 units of thromboplastin is the amount 
giving a coagulation time of 50 s in this test. Thromboplastin standards were fresh rabbit 
brain homogenates prepared in our laboratory and rabbit alveolar macrophage lysates. 
Duplicate measurements differed by <10%. 
To determine if coagulation factors other than factor V and tissue factor were present 
in the cultures, plasmas from patients with severe congenital monodeficiencies in factors 
V, VII, and X (from the Clinical Coagulation Laboratory, University of North Carolina, 
Chapel Hill,  NC) and  Dade factor II-deficient substrates (American Dade,  Miami, FL) 
were used in one-stage clotting tests. For these tests, 60/~1 of the culture supernatant or 
cell iysates was incubated with 60 ~1 of an excess of rabbit tissue factor standard at 37 ° C. 
After 30 s, 60 ul of 0.25  M CaCl2 plus 60 tA of substrate plasma was added and clotting 
times were measured in a Fibrometer. 
Chromogenic Assay  for Factor X or Xa.  The presence of factor X/Xa in the cultures was 
also  investigated  in  a  two-stage  test  using  the  chromogenic  substrate  S-2222  (Kabi 
Diagnostica, Stockholm, Sweden).  100 IA of culture supernatant or standard solution of 
purified factor X (0.1-0.001  units/ml), purified factor Xa (0.04-0.02 units/ml), or rabbit 
plasma dilutions of 1/50-1/5,000 were incubated with 15 #1 of 0.1  M CaCI2 and 25/~1 of 
Russell's viper venom (Sigma Chemical Co.) at 1 unit/ml. After 30 min at 37°C,  100 ul 
of the mixture was transferred to wells of microtiter plates (Dynatech Immulon, Scientific 
Products, Charlotte, NC) containing 50/~1 of 0.3 M Tris buffer, pH 8.3, and 100 #1 of S- 
2222. The incubation was continued for periods ranging from 5 min to 24 h. The reaction 
was stopped by adding 10 #1 of 50% acetic acid to each microwell and the optical density 
was read with a plate reader at 405 nm. 
Results 
Factor  V  Procoagulant  Activity  Is  Generated  by  Alveolar  Macrophages  in  Cul- 
ture.  Alveolar macrophages isolated  from rabbits and cultured  for 22  h  were 
examined for their ability to generate clotting factor V  using cells separated into 
five subpopulations  by Percoll  density  gradient  centrifugation.  With  this tech- 
nique,  the  cells  are  purified  at  several  stages  of maturation,  and  advancing 
maturity, characterized  morphometrically, correlates inversely with cell density 
(5).  Factor V  activity was found to be generated predominantly by intermediate 
density subpopulations of these macrophages. Thus, in six representative exper- 
iments, factor V  activity was not observed in assays before culture  using either 
intact  or  lysed  cells.  By  contrast,  factor  V  activity  was  consistently  found  in 
supernatants  harvested  from  22-h  cultures  containing  subpopulations  of inter- ROTHBERGER  AND  McGEE  1883 
mediate density (1.060,  1.064, and 1.068 g/ml; Table I). However, low density 
cells (1.055  g/ml) generated little or no measurable factor V activity (Table I). 
The highest-density subpopulation (1.070 g/ml) contained too few cells for study 
in half of the experiments shown (Table I). Additional studies were carried out 
using fewer cells (1  ×  106 rather  than  4  x  106 per culture).  In these smaller 
cultures, factor V activity was occasionally generated by the 1.070-g/ml subpop 
ulation, and when this occurred the amounts were comparable to those found 
with  intermediate-density  cells  cultured  under  the  same  conditions.  (In  the 
smaller  cultures,  1.055-g/ml  subpopulations  again  contrasted  with  remaining 
subpopulations by failing to generate factor V activity in detectable amounts and 
intermediate-density  subpopulations  consistently  generated  factor  V  activity.) 
Since only intermediate-density  cells consistently generated  factor  V  activity, 
data presented in the following experiments are for these cells only. 
Time-dependent Factor V Activity Generation by Alveolar Macrophages, Inhibition 
by Puromycin,  and Lack  of Stimulatory  Effects of Endotoxin.  Experiments  were 
carried out to examine the time course of factor V activity generation by alveolar 
macrophages. Activity was first detected in culture supernatants at 8 h, and by 
22 h, peak activity was reached (Fig.  1). Thereafter, activity declined. Including 
puromycin in the cultures at 0.1-10 t~g/ml inhibited the generation of factor V 
activity,  which indicates  requirements  for  protein  synthesis  (Fig.  2).  Dose-re- 
sponse studies showed that relatively low concentrations of puromycin inhibited 
generation of factor V activity as compared with tissue factor activity production 
TABLE  I 
Amounts of Factor V Activity Generated by Cultured Alveolar Macrophage Supopulations 
Factor V activity* 
Fraction number 
(percent total cells)*  Cell density  Thrombin  Ng  -Nrt 
Clotting time  equivalents 
U/ml 
1 (16%)  1.055  178 _+ 93  <19  2-6 
2 (39%)  1.060  51 +  6  75  6-6 
3 (34%)  1.064  54 +  5  69  5-5 
4 (9%)  1.068  60 +  5  55  5-6 
5 (<1%)  1.070  >500  <19  0-3 
Unfractionated  91 _  17  35  3-6 
cells 
Medium blank  >500  <19  6-6 
Amounts of factor V activity measured in 30/xl of supernatants from alveolar macrophage cultures 
containing 4 x  10  ~ cells/ml in 1 ml of serum-free medium are shown as clotting times in two-stage 
assays and alternatively as units of thrombin equivalents per milliliter. 
* Proportions of cells purified in each fraction are shown as a  percent of the total number of cells 
recovered from the density gradients. 
Factor V activity measured in seconds in a two-stage test is expressed as thrombin equivalents (or 
units) per milliliter as explained in Materials and Methods. Results are means for those experiments 
in which factor V was generated. 
g Ng-Nr represents the number of experiments in which measurable amounts of factor V activity 
were  generated,  followed by the number of times subpopulations were recovered from  Percoll 
gradients in numbers sufficient for culture and subsequent assay (e.g., fraction 1 contained sufficient 
cells for  study  in all  six  experiments,  but  factor  V  activity was generated  only twice,  and  the 
amounts were below limits of the assay, <19 units). 1884  ALVEOLAR  MACROPHAGE  FACTOR  V  ACTIVITY 
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FIGURE  1.  Alveolar macrophages of density 1.060 were cultured at 4  x  106 cells/ml for the 
time intervals indicated.  Supernatants and  cells were  harvested separately and amounts of 
factor V  activity were measured by a  two-stage coagulation assay.  The data show  factor V 
activity as thrombin units (or equivalents) per  milliter in  one of four  similar experiments. 
Factor V activity was found only in the supernatants, which indicates a  lack of intracellular 
accumulation of this procoagulant during culture. 
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FIGURE 2.  Alveolar macrophage cultures containing 4 x  106 cells/ml were assayed for both 
factor V and tissue factor activities. Amounts of procoagulant activity generation are shown 
as net increases per milliliter as compared with results before culture, and sensitivities to the 
protein  synthesis  inhibitor, puromycin,  are compared.  Data  are  for  one  of four  similar 
experiments. 
(Fig.  2).  Addition  of endotoxin  to  the  alveolar  macrophage  cultures  failed  to 
stimulate further increases of factor V  generation, but added endotoxin markedly 
stimulated tissue factor production  by the same cells (Table II). 
Characterization of Alveolar Macrophage Factor VIVa Activity by Specific Require- 
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TABLE  II 
Lack of Stimulatory Effects  on Factor V Activity Generation of 
Endotoxin Added to Cultures 
Endotoxin  Factor V activity*  Tissue factor activity* 
tag/ml  s  U/ml  s  U/ral 
0  68  50.0  65  7,470 (4,731) 
0.1  67  51.1  60  9,130 (6,391) 
1.0  70  43.5  43  28,220 (25,481) 
10.0  69  46.6  40  31,540 (28,801) 
Blank  >500  <19  >500  <1 
Alveolar macrophages of density 1.060 were cultured with the indicated 
concentrations  of added endotoxin for 24 h at 37°C. Data are from one 
experiment measuring Factor V and tissue factor in the same cultures. 
In three additional experiments using endotoxin as a stimulus (1 gg/ml), 
average  tissue factor activity increased  14-fold compared with levels in 
control cultures without added endotoxin, whereas generation of factor 
V activity was not stimulated in the same cultures (0.1-fold). 
* Amounts of factor  V were  measured in a  two-stage assay of culture 
supernatants as  described  in Table I.  Before  culture, factor  V  was 
undetectable in the cell preparations (clotting times were >500 s). 
* Tissue factor  was measured in a  one-stage  test  using cells recovered 
from the culture flaskette and lysed before assay. Results in parentheses 
indicate net changes of activity in culture compared with results before 
culture. The remaining data show actual  clotting times and units of 
activity measured after culture. 
TABLE  III 
Characterization of Factor V Activity Generated in Culture Using 
One-Stage Assays in Deficient  Substrate Plasmas 
II-  V-  VII-  X- 
Supernatants  107 + 3 (4)  55 4- 2 (5)  115 + 3 (5)  >250 (5) 
Lysates  124 ± 5 (4)  83 ± 2 (4)  114 ± 4 (4)  >250 (4) 
Saline control  119 ___ 5 (4)  82 __- 2 (4)  112 ± 5 (4)  >250 (4) 
The results shown are mean times (s + SEM) for assays of culture super- 
natants, lysates of cultured cells, and saline blanks in one-stage clotting 
factor assays using plasmas monodeficient  in the factors shown. The assays 
utilized  60 gl  of supernatant fluid or cell  lysate resuspended in fresh 
medium from 22-h alveolar macrophage  cultures, and the samples were 
tested in the presence of an excess of added tissue factor. The number of 
experiments performed is indicated, in parentheses. 
initially characterized in a  one-stage coagulation assay.  Supernatants from cul- 
tured  macrophages,  but  not  lysates  of these  cells,  corrected  the  coagulation 
defect  in  factor  V-deficient  substrate  plasmas.  Neither  supernatants nor  the 
lysates corrected defects in substrates deficient in factors,  II, VII, or X.  Thus, 
the procoagulant activity identified in supernatants is specifically factor V, and 
factor II, VII, and X  activities were not detected (Table III). 
Specific functional characterization of factor V  activity was also carried out by 
demonstrating strict requirements for factor Xa, prothrombin, lipid, and Ca  ++ 
for the formation of thrombin in a  two-stage test.  During the first stage of this 
assay, supernatants were incubated for 5 min with factor Xa, substrate (prothrom- 1886  ALVEOLAR  MACROPHAGE FACTOR  V ACTIVITY 
bin), lipid vesicles, and Ca ++ . For the second stage, the first reaction mixture was 
added  to  fibrinogen,  and  the  time  required  for fibrin clot formation  was  the 
measured endpoint.  Adding supernatants directly to fibrinogen did not induce 
fibrin formation, and all components of the first-stage mixture, including super- 
natants  plus  the  other  three  reactants,  were  found  to  be  needed  for  fibrin 
formation (Table IV). Thus, the procoagulant activity detected in culture super- 
natants  was  not  a  direct  prothrombinase,  but  it  amplified  the  effects of the 
classical prothrombinase, factor Xa, in a reaction dependent on lipids and Ca  ++. 
This observed specificity characterizes the supernatant procoagulant activity as 
factor V.  Pretreatment of supernatants  with catalytic amounts of thrombin did 
not significantly increase the amounts of factor V measured, which indicates that 
factor V  generated by cultured alveolar macrophages is in an activated (factor 
Va) form (9). (In three experiments, supernatants were preincubated with either 
thrombin or saline and diluted to avoid effects of added thrombin in the assay. 
In  the thrombin-and  saline-treated  supernatants,  amounts of factor V  activity, 
expressed as units of thrombin  equivalents per milliliter,  were 55.6  +  8.2  and 
51.0  _+  7,  respectively.  Buffer  blanks  containing  either  appropriately  diluted 
thrombin or saline had activities of <7.5 units/ml.) 
Control Experiments Showing a Lack in Alveolar Macrophages of  Factor V Activatible 
by Thrombin or Inhibitors of Factor V Activity.  In additional experiments, alveolar 
macrophages were studied either directly after isolation or after culture for 22 
h.  Lysates of the  uncultured  and  cultured  cells (separated  from supernatants) 
were pretreated with catalytic amounts of thrombin before assay in a  two-stage 
test. Factor V activity was not detected in these thrombin-treated cells. (Clotting 
times in two-stage tests were >500 s in assays using 4  ×  106 cells/ml, as routinely 
present in culture. Assays using excess numbers of uncultured and cultured cells, 
at  5  ×  107/ml,  gave similar  results,  i.e.,  clotting times were >500  s.)  In other 
experiments,  uncultured  and  cultured  cells at  a  concentration  of 4  x  106/ml 
were mixed with supernatants containing factor V  activity generated in culture. 
The mixtures were incubated at  37°C  for 30  min before assay in  a  two-stage 
test.  In  these  mixing  experiments,  there  was  no  evidence  found  to  indicate 
inhibitory effects of the cells on supernatant factor V activity (Table V). 
TABLE IV 
Effects of Deleting Components of the Factor Xa-dependent Prothrombinase Complex on Assay 
of Culture Supernatants for Factor V 
Component deleted and resultant clotting time (s) 
None  Lipids  Prothrombin  Fibrinogen  Xa  Ca  ++  Supernatant 
50  >500  >500  >500  >500  >500  >500 
Results are for a series of two-stage assays carried out as described in Table I after individually 
replacing components of the first-stage reaction mixture with saline. The resultant clotting time 
prolongations (as compared with the 50-s time obtained when none of the components were omitted) 
demonstrate that the macrophage procoagulant has specific requirements for each of the omitted 
reactants and  therefore is  factor  V.  The result  shown after replacing Ca  ++ with saline uses a 
supernatant dialysed to remove Ca  ++, which was a constituent of the culture medium. Using the 
undialysed supernatant containing Ca  ++, the clotting time was 121 s. ROTHBERGER  AND  McGEE  1887 
TABLE V 
Lack of Inhibition of Factor V Activity by Alveolar Macrophages 
Factor V activity 
Clotting time  (thrombin 
equivalents) 
s  U/ml 
63.0  60.1 
55.0  72.3 
56.5  69.0 
>500  <5.0 
>500  <5.0 
Supernatant + 
control medium 
Supernatant + 
cultured cells 
Supernatant + 
fresh cells 
Cultured cells 
Fresh cells 
Alveolar macrophages at 4 x  106 cells/ml were tested either directly after 
isolation  or  after  culture  for  22  h.  Cell  lysates  were  mixed  1:1  with 
supernatants containing factor V  activity generated in culture, and the 
mixtures were assayed for factor V activity in a two-stage test as described 
in Table 1.  Data show the means of duplicate assays from one of three 
similar experiments. 
Discussion 
The  present  experiments demonstrate that  coagulation  factor V  activity is 
generated by alveolar macrophages in culture. Thus,  factor V activity was not 
found in or on fresly isolated alveolar macrophages, even when excess numbers 
of cells were assayed following preincubation with thrombin, which was added 
in catalytic amounts to activate any inactive factor V in the cells. After initiating 
alveolar macrophage culture, amounts of factor V activity increased in a  time- 
dependent manner. Within ~8 h, the procoagulant attained readily measureable 
levels, and  peak amounts were reached by  22  h.  For generation of factor V 
activity, live cells synthesizing protein were required, as shown by results with 
controls containing iysed rather  than viable  cells and by inhibitory effects of 
puromycin included in the culture medium. Rather than being intracellular or 
on cell surfaces, the factor V activity was found in culture supernatants, which 
indicates that this procoagulant generated in its functional form is released from 
alveolar macrophages into the extracellular environment. Using Percoll density 
gradients to obtain a series of cells at different stages of maturation characterized 
morphometrically (5),  we found that alveolar macrophages are heterogeneous 
with  respect  to  their  ability  to  generate  factor  V  activity.  Macrophages  of 
intermediate maturity (and density) consistently generated this  activity, while 
fully mature (low density) cells generated little or none of the procoagulant. The 
least mature (most dense) subpopulation obtained, which accounted for <1% of 
the total cells, showed variable ability to generate factor V activity. 
In additional experiments, we found that addition of endotoxin to cultures 
did not stimulate generation of factor V activity. This contrasted with effects on 
tissue factor generation, which was stimulated by added endotoxin. Moreover, 
tissue factor generation was found at all stages of macrophage maturation in our 
earlier studies (5),  rather than being restricted to  cells at  particular  stages of 
maturity as  seen  here with  generation of factor V  activity.  Another contrast 1888  ALVEOLAR  MACROPHAGE  FACTOR  V  ACTIVITY 
observed was that inhibition of factor V generation occurred with relatively low 
concentrations of puromycin compared with amounts needed to inhibit genera- 
tion of tissue factor. Finally, alveolar macrophage tissue factor was found to be 
cell associated (5), while factor V activity was released into culture supernatants 
but was  not detectable on  macrophage surfaces  (intact  cell  measurements) or 
intracellularly (lysed cell measurements). 
Alveolar macrophages have not been previously shown to generate factor V 
activity or coagulation factors other than tissue factor. However, freshly isolated 
human monocytes and lymphocytes have been found to possess surface receptors 
for factor V, and addition of purified factors Va and Xa and Ca  ++ to these intact 
cells results in formation of a  functional prothrombinase complex (11).  Earlier 
reports (12, 13) suggested that factor V activity is produced by murine peritoneal 
macrophages simultaneously with prothrombin, factors VII, and Xa, tissue factor 
activities. These reports are apparently controversial (14).  A  subsequent study 
(15) showed that human monocytes have surface receptors for factor VII/VIIa, 
and the receptor in all likelihood is tissue factor. It has also been shown (14,  16, 
17) that rabbit hepatic macrophages, murine peritoneal exudate macrophages, 
and human monocytes generate factor VII-like or factor VII activity. 
In the present study, the assay for factor V  relied on demonstrating that a 
prothrombinase is formed by adding culture supernatants to mixtures containing 
a  prothrombin  substrate  together  with  purified  factor  Xa,  lipid  vesicles, and 
Ca ++.  Omitting  supernatants  or  any  of  these  reaction  mixture  components 
required for prothrombinase complex assembly resulted in a  loss of detectable 
prothrombinase  formation.  This  specificity characterizes  the  procoagulant  in 
supernatants as factor V.  Furthermore, the observed specific requirements for 
reaction  mixture components indicates a  lack of significant generation  by the 
macrophages of thrombin or prothrombinases independent of factor X (18,  19). 
Evidence  that  the  macrophages  generated  factor  V  activitiy  was  additionally 
confirmed by using a one-stage assay in substrate plasma severely monodeficient 
in factor V. Factors X/Xa, II, and VII were not detected in testing supernatants 
(or  cells)  in  an  amidolytic assay  for  factor  X/Xa  and  in  one-stage  assays  in 
substrates  monodeficient  in  these  factors.  Further  studies  will  be  needed  to 
elucidate the molecular structure of rabbit factor V, which, in contrast to human 
and bovine factor V, has not been isolated to date. 
The precise physiologic role of factor V activity produced by alveolar macro- 
phages is unknown. However, it is clear that the coagulation system provides a 
vital defense against lung hemorrhage. Moreover, in certain types of pulmonary 
inflammation,  the  process  of coagulation  within  alveolar  exudates  favorably 
affects hemodynamics and improves oxygenation (20). Tissue factor is available 
within the alveolus (5; McGee, M. P., and H. Rothberger, manuscript submitted 
for publication), and for thrombin formation to occur through the tissue factor 
(extrinsic) pathway in this extravascular space, sources of factors V, VII, II, and 
X  would be required.  As determined in studies of human and bovine plasma, 
factor V is by far the largest of the latter clotting proteins (330,000 vs. 50,000- 
70,000  daltons) (7,  21,  22).  Based on these differentials of molecular size and 
known characteristics  of alveolar  wall permeability (4),  it  seems likely that  in 
pulmonary inflammatory reactions accompanied by subtle capillary damage and ROTHBERGER AND McGEE  1889 
leakage of plasma, diffusion of factor V  from interstitial areas into the alveolar 
space would be relatively limited. Therefore, in these reactions, factor V activity 
generated by alveolar macrophages may serve to critically increase the rate of 
local thrombin  formation.  In  purified systems,  factor V  amplifies the rate of 
factor Xa catalysis of prothrombin to thrombin by more than 104-fold (7). 
Summary 
Alveolar macrophages are cells important in immune defense and inflamma- 
tion in the lung, and the coagulation system participates in these reactions. In 
earlier experiments, it was found that alveolar macrophages contain and produce 
tissue factor, the extrinsic clotting pathway activator. The present experiments 
explore possible  production  by alveolar  macrophages of the sequence of the 
clotting proteins that interact to form thrombin following initiation of coagula- 
tion by tissue factor. In studies using alveolar macrophages purified from rabbits, 
factor V  activity was  not  detected in  cell preparations  assayed directly after 
isolation. However, after short-term culture, we found generation and release of 
factor V  activity by these cells, which was predominantly from subpopulations 
with  densities  of  1.060-1.068  g/ml,  corresponding to  intermediate stages  of 
alveolar macrophage maturation.  Cell  viability and protein  synthesis were re- 
quired for generation of the activity as shown by inhibitory effects of cell lysis 
before culture and by effects observed after including puromycin in  cultures 
with  viable  cells.  The  activity  generated  was  characterized  as  factor  V  by 
demonstrating specific functional requirements in one- and two-stage coagulation 
tests. There was no detectable generation in these cultures of factors II, VII, X, 
or the more recently described factor X-independent monocyte/macrophage 
prothrombinases.  Factor  V  activity  generated  by  alveolar  macrophages  may 
contribute to prothrominase assembly, activation of  clotting, and fibrin formation 
within the alveolus. 
Jeff Hoffman and Judy Merkel provided expert technical assistance. 
Received  for publication  19July 1984 and in revised form 5 September 1984. 
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